Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...

China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...

Results of CHANCE 2005/CARES-005 study were unveiled by Dr Gao-Jun Teng from Zhongda Hospital, Southeast University, China, ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...